Novartis Nederland

What Novartis Nederland does

Novartis Nederland (legal entity Novartis Pharma B.V.) is the Dutch commercial and clinical research subsidiary of Switzerland-based Novartis AG. Operating from Amsterdam with approximately 137 employees, the entity markets a portfolio of innovative prescription medicines across eight therapeutic areas — cardiovascular, immunology, neurology, oncology, ophthalmology, rare disease, hematology, and respiratory — including Entresto, Leqvio, Cosentyx, Xolair, Jakavi, Revolade, Scemblix, Aimovig, Kesimpta, Kisqali, Mekinist, Tafinlar, Beovu, Lucentis, Luxturna, and Ilaris.

The business model is enterprise field sales to Dutch hospitals and healthcare professionals, supplemented by a dedicated physician portal (artsenportaal) for prescriber engagement. Revenue is generated through reimbursement-funded sales of patented, regulator-approved innovative medicines; no direct-to-consumer channel is operated. The entity also functions as a clinical research hub for the parent, enrolling approximately 1,800 Dutch patients across more than 80 clinical studies in 2024 and receiving R&D Top 50 recognition in 2025.

Novartis Nederland does not disclose country-level revenue, and its scale is best understood as a mid-sized European country subsidiary within a global top-five pharmaceutical group. The unit has no disclosed AI/ML capabilities, no acquisitions, and no independent funding events, consistent with its role as a wholly-owned commercialization and clinical-trial execution arm rather than an independent operating company.

Name

Novartis Nederland

Legal name

Novartis Pharma B.V.

Website

https://novartis.nl

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

Novartis Nederland (Novartis Pharma B.V.) is the Dutch subsidiary of Novartis AG, commercializing innovative prescription medicines across eight therapeutic areas through enterprise field sales to Dutch hospitals and healthcare professionals.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Innovative medicines
• Prescription pharmaceuticals
• Oncology treatments
• Cardiometabolic therapies
• Clinical research

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical product sales: Novartis generates revenue through the sale of prescription pharmaceutical medicines across multiple therapeutic areas including cardiology, dermatology, hematology, neurology, oncology, ophthalmology, pulmonology, and rheumatology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Novartis Nederland sells and supports a portfolio of innovative prescription pharmaceutical medicines across eight therapeutic areas: cardiology, dermatology, hematology, neurology, oncology, ophthalmology, pulmonology, and rheumatology. The subsidiary operates clinical research programs in the Netherlands, partnering with Dutch hospitals to advance patient care, and provides a healthcare professional portal for product information and accredited education.

Product overview

Novartis Nederland is the Dutch subsidiary of Novartis, a pharmaceutical company focused on innovative medicines. The company offers a portfolio of prescription medications across multiple therapeutic areas including Cardiology (Entresto, Leqvio), Dermatology (Cosentyx HS, Cosentyx PsO, Xolair CSU), Hematology (Jakavi MF, Revolade, Scemblix), Neurology (Aimovig, Kesimpta), Oncology (Kisqali, Mekinist, Tafinlar), Ophthalmology (Beovu, Lucentis, Luxturna), Pulmonology (Xolair CRSwNP, Xolair SAA), and Rheumatology (Cosentyx, Ilaris). The company also provides a healthcare provider portal (pro.novartis.com) for professional information, accredited training, and practical materials for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Products and services

• Entresto Cardiovascular prescription medication for the treatment of heart failure, offered to healthcare professionals in the Netherlands.
• Leqvio Cardiovascular prescription medication for the treatment of hypercholesterolemia, offered to healthcare professionals in the Netherlands.
• Cosentyx HS Prescription dermatology medication for the treatment of Hidradenitis Suppurativa (HS), offered to Dutch healthcare professionals.
• Cosentyx PsO Prescription dermatology medication for the treatment of Psoriasis (PsO), offered to Dutch healthcare professionals.
• Xolair CSU Prescription dermatology medication for the treatment of Chronic Spontaneous Urticaria (CSU), offered to Dutch healthcare professionals.
• Jakavi MF Prescription hematology medication for the treatment of Myelofibrose (MF), offered to Dutch healthcare professionals.
• Revolade Prescription hematology medication for hematological conditions, offered to Dutch healthcare professionals.
• Scemblix Prescription hematology medication for the treatment of hematological malignancies, offered to Dutch healthcare professionals.
• Aimovig Prescription neurology medication for the treatment of migraine, offered to Dutch healthcare professionals.
• Kesimpta Prescription neurology medication for the treatment of Multiple Sclerose (MS), offered to Dutch healthcare professionals.
• Kisqali Prescription oncology medication for the treatment of breast cancer, offered to Dutch healthcare professionals.
• Mekinist Prescription oncology medication for the treatment of melanoma and other cancers, offered to Dutch healthcare professionals.
• Tafinlar Prescription oncology medication for the treatment of melanoma and other cancers, offered to Dutch healthcare professionals.
• Beovu Prescription ophthalmology medication for the treatment of eye conditions, offered to Dutch healthcare professionals.
• Lucentis Prescription ophthalmology medication for the treatment of retinal diseases, offered to Dutch healthcare professionals.
• Luxturna Gene therapy for the treatment of inherited retinal diseases, offered to Dutch healthcare professionals.
• Xolair CRSwNP Prescription medication for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), offered to Dutch healthcare professionals.
• Xolair SAA Prescription medication for the treatment of Severe Allergic Asthma (SAA), offered to Dutch healthcare professionals.
• Cosentyx Prescription rheumatology medication for the treatment of axial spondyloarthritis and psoriatic arthritis, offered to Dutch healthcare professionals.
• Ilaris Prescription rheumatology medication for the treatment of periodic fever syndromes and other inflammatory conditions, offered to Dutch healthcare professionals.

Quantifiable outcome

• Approximately 1,800 Dutch patients participated in 80+ clinical studies in 2024

Segments8 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Dutch hospitalscoreStrategic or Co-development PartnerNovartis collaborates closely with Dutch hospitals for clinical research. In 2024, approximately 1,800 Dutch patients participated in over 80 clinical studies conducted in partnership with Dutch healthcare institutions.
• Dutch researchers and healthcare professionalscoreStrategic or Co-development PartnerNovartis works with researchers and healthcare professionals in the Netherlands to advance medical innovation and patient care. The strong collaboration contributes to the Netherlands' position as an important hub for clinical research in Europe.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Roche Nederland: Dutch affiliate of F. Hoffmann-La Roche, a global innovator with strong oncology, immunology, ophthalmology, and diagnostics franchises. Directly comparable as a Netherlands-based subsidiary of a Swiss-headquartered, R&D-intensive branded pharma parent.
• Bristol-Myers Squibb Nederland: Dutch affiliate of BMS, a global branded pharma innovator focused on oncology, hematology, immunology, and cardiovascular disease. Comparable as a Netherlands-based subsidiary of an innovator pharma parent with overlapping therapeutic areas.
• Bayer Nederland: Dutch affiliate of Bayer AG, marketing branded pharmaceuticals across cardiology, women's health, oncology, and radiology — comparable as a Netherlands operating entity of a large German-headquartered innovator with specialty-pharma depth.
• MSD Nederland (Merck & Co.): Dutch affiliate of Merck & Co., a global innovator with leading oncology (Keytruda), vaccines, and specialty franchises. Comparable as a Netherlands-based operating entity of a publicly listed pharma parent with similar enterprise field-sales motion.
• Janssen Nederland (Johnson & Johnson Innovative Medicine): Dutch affiliate of Johnson & Johnson's Innovative Medicine arm, marketing branded specialty pharma across oncology, immunology, neuroscience, and pulmonary hypertension — a closely comparable specialty-innovator affiliate.
• GSK Nederland: Dutch affiliate of GSK, a global branded pharma company operating across specialty medicines, vaccines, and HIV. Directly comparable in scope of Netherlands operations and enterprise-HCP GTM motion.
• Pfizer Nederland: Dutch affiliate of Pfizer Inc., a global branded pharmaceutical innovator marketing prescription medicines across oncology, cardiology, vaccines, neurology, and rare diseases — directly comparable in therapeutic breadth, GTM model, and country-level structure to Novartis Nederland.
• AstraZeneca Nederland: Dutch affiliate of AstraZeneca, marketing branded innovative medicines across oncology, cardiovascular-renal-metabolic, and respiratory diseases — a directly comparable specialty-pharma affiliate operating under the same enterprise field-sales model.
• Eli Lilly Nederland: Dutch affiliate of Eli Lilly, marketing branded innovative medicines in oncology, immunology, diabetes, and neurology. Comparable as a Netherlands operating entity of a US-headquartered innovator pharma parent.
• Sanofi Nederland: Dutch affiliate of Sanofi, marketing branded specialty and primary-care pharmaceuticals including immunology (Dupixent), neurology, and rare-disease products. Closely comparable in scope of specialty therapeutic areas and country-level GTM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartis-pharma-nederland

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Nederland